NCT04167696View on ClinicalTrials.gov

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02

PHASE1RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

November 25, 2019

Primary Completion Date

December 31, 2021

Study Completion Date

February 28, 2035

Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Interventions
BIOLOGICAL

CYAD-02

CYAD-02 is a Chimeric Antigen Receptor-T (CAR-T) administered after CYFLU.

DRUG

ENDOXAN

administered as preconditioning chemotherapy

DRUG

Fludara

administered as preconditioning chemotherapy

Trial Locations (5)

3000

RECRUITING

Uz Leuven, Leuven

4000

RECRUITING

Chu Liege, Liège

8800

RECRUITING

AZ DELTA, Roeselare

32224

NOT_YET_RECRUITING

Mayo Clinic Cancer Center, Jacksonville

66205

RECRUITING

University of Kansas Cancer Center, Fairway

Sponsors

Lead Sponsor

Celyad Oncology SA
All Listed Sponsors
lead

Celyad Oncology SA

INDUSTRY

NCT04167696 - Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 | Biotech Hunter | Biotech Hunter